tradingkey.logo

Cerus Corp

CERS
2.060USD
-0.060-2.83%
Close 12/23, 16:00ETQuotes delayed by 15 min
395.60MMarket Cap
LossP/E TTM

Cerus Corp

2.060
-0.060-2.83%

More Details of Cerus Corp Company

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Cerus Corp Info

Ticker SymbolCERS
Company nameCerus Corp
IPO dateJan 31, 1997
CEOGreenman (William M)
Number of employees281
Security typeOrdinary Share
Fiscal year-endJan 31
Address1220 Concord Avenue
CityCONCORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94520
Phone19252886000
Websitehttps://www.cerus.com/
Ticker SymbolCERS
IPO dateJan 31, 1997
CEOGreenman (William M)

Company Executives of Cerus Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Mr. Dean A. Gregory
Mr. Dean A. Gregory
Director
Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product
52.45M
0.00%
By RegionUSD
Name
Revenue
Proportion
North America
35.29M
67.28%
Europe and Middle East and Africa
16.61M
31.68%
Other
547.00K
1.04%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
52.45M
0.00%

Shareholding Stats

Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
9.81%
BlackRock Institutional Trust Company, N.A.
8.11%
The Vanguard Group, Inc.
5.61%
Baker Bros. Advisors LP
5.21%
Amova Asset Management Co., Ltd.
2.96%
Other
68.29%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
9.81%
BlackRock Institutional Trust Company, N.A.
8.11%
The Vanguard Group, Inc.
5.61%
Baker Bros. Advisors LP
5.21%
Amova Asset Management Co., Ltd.
2.96%
Other
68.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.57%
Investment Advisor/Hedge Fund
21.33%
Hedge Fund
15.03%
Individual Investor
4.65%
Research Firm
2.24%
Family Office
1.26%
Venture Capital
0.15%
Bank and Trust
0.10%
Pension Fund
0.05%
Other
23.63%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
268
135.44M
74.92%
--
2025Q3
304
135.48M
76.42%
-3.67M
2025Q2
319
139.46M
80.29%
-3.80M
2025Q1
331
143.27M
81.50%
-8.15M
2024Q4
348
140.37M
85.99%
-4.57M
2024Q3
355
141.38M
83.08%
+1.94M
2024Q2
369
139.61M
83.57%
+2.55M
2024Q1
368
136.85M
84.80%
-16.89M
2023Q4
369
136.19M
88.68%
-5.81M
2023Q3
366
140.75M
85.17%
+728.73K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
19.21M
10.02%
-1.45M
-7.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.43M
8.05%
+2.50M
+19.30%
Jun 30, 2025
The Vanguard Group, Inc.
10.72M
5.59%
+168.09K
+1.59%
Jun 30, 2025
Baker Bros. Advisors LP
12.88M
6.72%
-6.47M
-33.42%
Jun 30, 2025
Amova Asset Management Co., Ltd.
6.07M
3.17%
-121.05K
-1.96%
Jun 30, 2025
Wasatch Global Investors Inc
8.53M
4.45%
+213.92K
+2.57%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.35M
2.27%
-193.16K
-4.25%
Jun 30, 2025
BlackRock Financial Management, Inc.
4.16M
2.17%
+2.94M
+242.32%
Jun 30, 2025
Silvercrest Asset Management Group LLC
3.49M
1.82%
+3.79K
+0.11%
Jun 30, 2025
Senvest Management, LLC
4.01M
2.09%
-400.00K
-9.08%
Jun 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
0.89%
Invesco NASDAQ Future Gen 200 ETF
0.6%
ARK Innovation ETF
0.18%
Fidelity Enhanced Small Cap ETF
0.06%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares US Small-Cap Equity Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
ARK Genomic Revolution ETF
Proportion0.89%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
ARK Innovation ETF
Proportion0.18%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares US Small-Cap Equity Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Cerus Corp?

The top five shareholders of Cerus Corp are:
ARK Investment Management LLC holds 19.21M shares, accounting for 10.02% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 15.43M shares, accounting for 8.05% of the total shares.
The Vanguard Group, Inc. holds 10.72M shares, accounting for 5.59% of the total shares.
Baker Bros. Advisors LP holds 12.88M shares, accounting for 6.72% of the total shares.
Amova Asset Management Co., Ltd. holds 6.07M shares, accounting for 3.17% of the total shares.

What are the top three shareholder types of Cerus Corp?

The top three shareholder types of Cerus Corp are:
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

How many institutions hold shares of Cerus Corp (CERS)?

As of 2025Q4, 268 institutions hold shares of Cerus Corp, with a combined market value of approximately 135.44M, accounting for 74.92% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.49%.

What is the biggest source of revenue for Cerus Corp?

In FY2025Q2, the Product business generated the highest revenue for Cerus Corp, amounting to 52.45M and accounting for --% of total revenue.
KeyAI